SecBot SecBot
8-K ·Filed Nov 3, 2026

DNLI

Denali Therapeutics Inc.
BULLISH
Impact 6/10
Horizonmonths Processed13d 9h ago SEC0001714899-26-000107
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The rapid AVLAYAH revenue ramp and strong Q4 guidance validate commercial execution and support the platform thesis. Watch for Q4 actuals and the zafinofusp alfa BLA submission in 2027, which would be the second product approval.

DirectionBullish
Confidencehigh
Horizonmonths

tividenofusp alfa-eknm

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
Next catalyst
None dated

What to watchThe next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.

Price Chart

Loading chart...

Executive Summary

Denali reported Q3 2026 AVLAYAH net product revenue of $17.8M, accelerating from $3.6M in Q2, and guided Q4 2026 revenue to $30M-$32M. Net income of $70.1M included a one-time $194M gain on a Priority Review Voucher sale. The company ended the quarter with $1.0B in cash and reiterated a 2027 BLA submission for zafinofusp alfa seeking accelerated approval.

Key Financial Metrics

EPS
$0.37
Revenue
$17.8M
est $22.9M · -22.4%
Guidance
$30.0M-$32.0M
initiated

Key Facts

  • AVLAYAH net product revenue accelerated to $17.8M in Q3 2026, its second full commercial quarter
  • Q4 2026 net product revenue guidance of $30.0M to $32.0M
  • Net income of $70.1M included a one-time $194.0M net gain on sale of a Priority Review Voucher
  • Cash, cash equivalents and marketable securities were approximately $1.0B as of September 30, 2026
  • BLA submission for zafinofusp alfa (Sanfilippo syndrome type A) on track for 2027 seeking accelerated approval
  • Five TransportVehicle programs expected to generate data in 2027
  • Payer coverage now exceeds 70% of U.S. commercial lives, up from more than 50% in the prior quarter
  • A permanent J-code became effective October 1, 2026, streamlining billing and reimbursement

Financial Impact

AVLAYAH revenue grew from $3.6M in Q2 to $17.8M in Q3, with Q4 guidance of $30M-$32M indicating continued acceleration. The company holds $1.0B in cash.

revenuecash position

Risk Factors

  • AVLAYAH revenue growth may not sustain at the guided Q4 rate due to patient population size or payer dynamics
  • Zafinofusp alfa BLA submission and accelerated approval remain subject to FDA review and data adequacy
  • Net income was driven by a one-time PRV gain; operating losses continue

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001714899-26-000107
Document: dnli-20261103.htm0001714899-26-000107
Document: 0001714899-26-000107-index-headers.html0001714899-26-000107
Document: 0001714899-26-000107-index.html0001714899-26-000107
Document: 0001714899-26-000107.txt0001714899-26-000107
8-K Data (Synthetic)0001714899-26-000107

Track record

17 reports on DNLI

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026